 Saint- Herblain France, July 1 , 2021 Following a media article published yesterday, Valneva SE, Nasdaq: VALN; Euronext Paris: VLA, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, indicated today it continues ongoing discussions with the European Commission regarding VLA2001, Valnevas inactivated COVID-19 vaccine candidate. 